UK

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority responsible for overseeing the safety, quality, and efficacy of medicines, medical devices, diagnostics, and digital health technologies in the United Kingdom. Since the UK's departure from the European Union, the MHRA operates as a fully independent regulator, no longer bound by the European Medicines Agency (EMA) centralised procedure for new market authorisations. The principal legislative frameworks governing health product regulation include the Human Medicines Regulations 2012 (as amended), the Medical Devices Regulations 2002 (as amended by the Medical Devices (Amendment) (Great Britain) Regulations 2023), and the Medicines Act 1968, supplemented by guidance from NICE, NHS England, and devolved health authorities in Scotland, Wales, and Northern Ireland.

For pharmaceuticals, sponsors may pursue several authorisation routes including the National Procedure, the Decentralised Procedure (for legacy mutual recognition products), and the new International Recognition Procedure (IRP), which allows the MHRA to rely on decisions from trusted reference agencies such as the EMA, FDA, Health Canada, TGA, and Swissmedic. Submissions are accepted in Common Technical Document (CTD) format, and a UK-based Marketing Authorisation Holder or Applicant is required. For medical devices and diagnostics, a new UK Conformity Assessed (UKCA) marking regime is being phased in for Great Britain, while CE marking continues to be accepted under a transitional arrangement extended through 2028. Northern Ireland retains alignment with EU MDR and IVDR frameworks under the Windsor Framework. Notable recent reforms include the introduction of the Innovative Licensing and Access Pathway (ILAP), Statutory Advice schemes for novel health technologies, and a strengthened post-market surveillance framework for devices. The MHRA has also published a Software and AI as a Medical Device roadmap to address emerging digital health regulation.

Public procurement of health products in the UK is primarily coordinated through NHS England at the national level, with NHS Supply Chain serving as the central purchasing body responsible for sourcing medicines, medical devices, consumables, and capital equipment on behalf of NHS trusts and integrated care systems (ICSs) across England. NHS Supply Chain operates category towers and framework agreements that suppliers must qualify onto in order to access the NHS market at scale. Separate but broadly aligned procurement frameworks operate in Scotland (National Procurement, Scottish Government Health and Social Care Directorates, NHS National Services Scotland), Wales (NHS Wales Shared Services Partnership), and Northern Ireland (Health and Social Care Business Services Organisation). The UK follows the Procurement Act 2023, which replaced the Public Contracts Regulations 2015 and introduced new transparency obligations, flexibility provisions, and a broader definition of public interest, all relevant to health product tenders. Formulary listing and clinical adoption are additionally governed by health technology assessment (HTA) recommendations from NICE in England and Wales, the Scottish Medicines Consortium (SMC) in Scotland, and the All Wales Medicines Strategy Group (AWMSG), all of which influence whether a product is reimbursed and at what price within NHS settings.

The private sector in the UK plays a meaningful role in health product procurement, encompassing private hospitals, independent diagnostic laboratories, pharmacy chains, and digital health platforms, all of which procure through direct commercial agreements rather than NHS frameworks. The UK is predominantly a high-income domestic-funded market and does not rely on multilateral donor procurement channels such as UNICEF Supply Division, the Global Fund, or USAID for mainstream health product access. However, UK-based manufacturers and distributors may participate in global donor-funded tenders through these bodies for export markets, and the UK government, via the Foreign, Commonwealth and Development Office (FCDO), funds global health procurement programmes internationally. There is no formal local manufacturing preference policy embedded in NHS procurement rules, though the government has prioritised health supply chain resilience and domestic manufacturing capacity following COVID-19 disruptions, reflected in initiatives such as the Life Sciences Vision, Vaccine Manufacturing and Innovation Centre (VMIC) investments, and the NHS Commercial Framework for New Medicines, which incorporates managed access and outcomes-based agreements to balance innovation incentives with affordability.